Cite
MLA Citation
Joel M. Kremer et al.. “A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy.” Arthritis & rheumatology, vol. 68, no. 12, 2016, pp. 2867–2877. http://access.bl.uk/ark:/81055/vdc_100039463789.0x000001